KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Net Margin (2016 - 2025)

Neogenomics (NEO) has disclosed Net Margin for 16 consecutive years, with 5.2% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 371.0% year-over-year to 5.2%, compared with a TTM value of 14.85% through Dec 2025, down 293.0%, and an annual FY2025 reading of 14.85%, down 293.0% over the prior year.
  • Net Margin was 5.2% for Q4 2025 at Neogenomics, up from 14.45% in the prior quarter.
  • Across five years, Net Margin topped out at 62.33% in Q2 2021 and bottomed at 42.17% in Q1 2022.
  • Average Net Margin over 5 years is 14.53%, with a median of 16.46% recorded in 2022.
  • The sharpest move saw Net Margin skyrocketed 7018bps in 2021, then crashed -9056bps in 2022.
  • Year by year, Net Margin stood at 33.21% in 2021, then soared by 51bps to 16.36% in 2022, then soared by 44bps to 9.21% in 2023, then rose by 3bps to 8.91% in 2024, then soared by 42bps to 5.2% in 2025.
  • Business Quant data shows Net Margin for NEO at 5.2% in Q4 2025, 14.45% in Q3 2025, and 24.87% in Q2 2025.